Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Social distancing

- PMLiVE

Moderna expects to supply 125 million COVID-19 vaccine doses in Q1 2021

85 million to 100 million doses will be available in the US

- PMLiVE

NIAID chief back-pedals on criticism of UK’s Pfizer vaccine approval process

Anthony Fauci apologised for previous comments in BBC interview

Designing Ethical AI and Healthcare Technologies

Bryn Williams-Jones, Professor & Director of the Bioethics Program at ESPUM and Editor-in-Chief of the Canadian Journal of Bioethics discusses the bioethical challenges of innovative healthcare technologies such as AI, digital therapeutics,...

Impetus Digital

https://youtu.be/5jUf-4v_g7w

Attacking COVID-19 from All Angles

Michael Taylor, CEO & Founder of Environmental Surface Solutions, explores alternative and supplementary approaches to fighting COVID-19 and other pathogens. In particular, we focus on environmental solutions for not only eradicating...

Impetus Digital

- PMLiVE

Questions surrounding remdesivir treatment for COVID-19 are ‘complicated’, says NEJM

Editorial highlights issues with WHO’s Solidarity trial

- PMLiVE

US secures 650,000 additional doses of Lilly’s COVID-19 antibody

This takes the total purchased amount to 950,000 doses

- PMLiVE

WHO set to review Pfizer/BioNTech COVID-19 vaccine for emergency use listing

Follows approval for emergency use in the UK yesterday

- PMLiVE

EMA launches rolling review of J&J’s COVID-19 vaccine

Vaccine entered phase 3 testing in September

- PMLiVE

Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial

Company also completes enrolment in UK-based phase 3 trial

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine gets first approval from UK

The UK has already signed a supply deal for 40 million doses

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

Moderna eyes COVID-19 vaccine approval in the US and the EU

Updated analysis demonstrates efficacy of 94.1%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links